FDA Approves Dabrafenib/Trametinib Combo for BRAF+ NSCLC

June 22, 2017 – The FDA approved the combination of dabrafenib and trametinib for patients with BRAF V600–positive advanced or metastatic non–small cell lung cancer (NSCLC). The agency gave the combination breakthrough designation for patients with BRAF V600E­–mutant NSCLC, which has been associated with poorer prognosis, in 2015. The European Union approved the dabrafenib/trametinib combination in April. The FDA also approved the … (leggi tutto)